Divis Laboratories' Q1 FY 2025-26 Quarterly Results
- 07 Aug 2025
Result Summary
- Divis Laboratories Ltd reported a 6.2% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 15.1%.
- Its expenses for the quarter were up by 7.6% QoQ and 12.7% YoY.
- The net profit increased 1.3% QoQ and increased 26.7% YoY.
- The earnings per share (EPS) of Divis Laboratories Ltd stood at 20.5 during Q1 FY 2025-26.
Financial Statments for Q1 FY 2025-26
Total Income | 2529.00 | 2382.00 | 2197.00 | 6.2% | 15.1% |
Total Expenses | 1796.00 | 1669.00 | 1593.00 | 7.6% | 12.7% |
Profit Before Tax | 733.00 | 713.00 | 604.00 | 2.8% | 21.4% |
Tax | 188.00 | 175.00 | 174.00 | 7.4% | 8.0% |
Profit After Tax | 545.00 | 538.00 | 430.00 | 1.3% | 26.7% |
Earnings Per Share | 20.50 | 20.30 | 16.20 | 1.0% | 26.5% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Divis Laboratories Ltd is a leading player in the pharmaceutical industry, primarily focused on the manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. The company is known for its significant contribution to the global pharmaceutical supply chain. Divis Laboratories operates in a highly competitive market, catering to both domestic and international clients. The company has been continually investing in innovation and expanding its production capabilities to meet the growing demand for pharmaceutical products. Recent developments in the company may include expansion in its manufacturing facilities and introduction of new products to its portfolio, although specific details on the same are not available at this moment.
Revenue
In the first quarter of the fiscal year 2026, Divis Laboratories Ltd reported a total income of ₹2,529 crore. This represents a 6.2% increase quarter-over-quarter (QoQ) from ₹2,382 crore in the previous quarter (Q4FY25). Additionally, there was a notable year-over-year (YoY) growth of 15.1% compared to ₹2,197 crore in the corresponding quarter of the previous fiscal year (Q1FY25). This upward trend in revenue indicates a consistent increase in the company's sales and market presence over the past year.
Profitability
For Q1FY26, Divis Laboratories Ltd recorded a profit before tax of ₹733 crore, reflecting a QoQ growth of 2.8% from ₹713 crore in Q4FY25, and a significant YoY increase of 21.4% from ₹604 crore in Q1FY25. The tax expense for the quarter was ₹188 crore, which saw a 7.4% rise from the previous quarter and an 8.0% rise YoY. Profit after tax stood at ₹545 crore, registering a 1.3% QoQ growth from ₹538 crore and a substantial 26.7% YoY increase from ₹430 crore. Earnings per share (EPS) also rose to ₹20.50, marking a 1.0% increase QoQ and 26.5% YoY, highlighting the company's improved profitability metrics over the periods considered.
Operating Metrics
Total expenses for Divis Laboratories Ltd in Q1FY26 amounted to ₹1,796 crore, up by 7.6% from ₹1,669 crore in the preceding quarter and 12.7% from ₹1,593 crore in the same quarter of the previous year. Despite the rise in expenses, the company maintained a strong profit margin. The calculated profit margin before tax for Q1FY26 was approximately 28.98%, slightly lower than the 29.93% in Q4FY25 but higher than the 27.49% in Q1FY25, indicating efficient cost management alongside revenue growth. These metrics highlight the company's ability to manage its operational costs while still expanding its revenue base.